# Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

> **NCT04309136** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 13 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Anlotinib
- **PROCEDURE:** surgery
- **PROCEDURE:** core needle biopsy

## Key facts

- **NCT ID:** NCT04309136
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2021-02-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04309136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04309136, "Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04309136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*